Advancing Pharmacogenomics in the UK
More than 20 years ago, the Human Genome Project mapped the genes that make us who we are, paving the way for using information about an individual’s genes in healthcare. ‘Pharmacogenomics’ studies how our genes influence our response to medicines. We know that differences in our genes can determine whether a medicine works well, fails to work, or causes series side effects. Pharmacogenomic knowledge is now at a stage where it can benefit people receiving medical treatment.
The Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) is dedicated to accelerating the safe and effective use of pharmacogenomics in healthcare. We develop guidelines, industry pathways, and educational platforms to support regulators, healthcare professionals, and researchers, while ensuring patient and public input shapes the future of genomic medicine.
Through collaboration across academia, industry, and the NHS, our goal is to make precision medicine a reality, improving patient outcomes and fostering innovation across the UK.
Contact:
Angela Cucchi, Project Co-Ordinator, angela.cucchi@liverpool.ac.uk
Our supporting partners:
What is CERSI-PGx?
-
PPIE Publication
We are pleased to share the publication of our paper, “Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross-sectional analysis,”…
-
New CERSI-PGx Clinical Guidelines: HLA Genotyping for carbamazepine, oxcarbazepine and eslicarbazepine
We are delighted to share the publication of the second CERSI-PGx guideline on the use of HLA testing to optimise the prescribing of carbamazepine, oxcarbazepine…
-
New CERSI-PGx Clinical Guidelines: Universal CYP2C19 Genotyping for Clopidogrel Prescribing
CERSI-PGx has published comprehensive UK clinical guidelines recommending universal CYP2C19 genotype testing for patients prescribed clopidogrel. Covering stroke, coronary artery disease, and peripheral arterial disease,…
Read more News & Events articles →